Resiquimod

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by SmackBot (talk | contribs) at 17:18, 24 June 2009 (Standard headings/general fixes). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Resiquimod
Clinical data
Pregnancy
category
  • AU: B1
Routes of
administration		Topical
Legal status
Legal status
Identifiers
  • 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H22N4O2
Molar mass314.382 g/mol g·mol−1
3D model (JSmol)
  • CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical cream in the treatment of skin lesions[1] such as those caused by herpes simplex virus,[2][3] and as an adjutant to increase the effectiveness of vaccines.[4] It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8,[5] and an upregulator of the opioid growth factor receptor.[6]

See also

References

  1. ^ Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC (2008). "A phase II dose-ranging study of topical resiquimod to treat actinic keratosis". The British Journal of Dermatology. 159 (1): 205–10. doi:10.1111/j.1365-2133.2008.08615.x. PMID 18476957. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. ^ Wu JJ, Huang DB, Tyring SK (2004). "Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses". Antiviral Research. 64 (2): 79–83. doi:10.1016/j.antiviral.2004.07.002. PMID 15498602. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  3. ^ Fife KH, Meng TC, Ferris DG, Liu P (2008). "Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions". Antimicrobial Agents and Chemotherapy. 52 (2): 477–82. doi:10.1128/AAC.01173-07. PMC 2224757. PMID 18039918. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  4. ^ Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP (2007). "Resiquimod and other immune response modifiers as vaccine adjuvants". Expert Review of Vaccines. 6 (5): 835–47. doi:10.1586/14760584.6.5.835. PMID 17931162. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ Hurst J, Prinz N, Lorenz M, Bauer S, Chapman J, Lackner KJ, von Landenberg P (2009). "TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells". Immunobiology. doi:10.1016/j.imbio.2008.12.003. PMID 19249118. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  6. ^ Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ (2008). "Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function". Experimental Biology and Medicine (Maywood, N.J.). 233 (8): 968–79. doi:10.3181/0802-RM-58. PMID 18480416. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Resiquimod&oldid=298390898"